166 related articles for article (PubMed ID: 31397441)
1. [Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors].
Shaheen A; Afridi WA; Mahboob S; Sana M; Zeeshan N; Ismat F; Mirza O; Iqbal M; Rahman M
Mol Biol (Mosk); 2019; 53(4):674-684. PubMed ID: 31397441
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
3. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
[TBL] [Abstract][Full Text] [Related]
4. Restraining the multidrug efflux transporter STY4874 of Salmonella Typhi by reserpine and plant extracts.
Tariq A; Sana M; Shaheen A; Ismat F; Mahboob S; Rauf W; Mirza O; Iqbal M; Rahman M
Lett Appl Microbiol; 2019 Sep; 69(3):161-167. PubMed ID: 31267555
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel 4-substituted quinazoline-2-carboxamide derivatives targeting AcrB to reverse the bacterial multidrug resistance.
Gu X; Pisoni LA; Wang Y; Song D; Sykes MJ; Qin Y; Semple SJ; Polyak SW; Venter H; Ma S
Bioorg Chem; 2020 Dec; 105():104394. PubMed ID: 33120321
[TBL] [Abstract][Full Text] [Related]
9. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
[TBL] [Abstract][Full Text] [Related]
10. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
Schuster S; Vavra M; Wirth DAN; Kern WV
Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
[TBL] [Abstract][Full Text] [Related]
11. Cloning and Functional Characterization of Putative
Feng Z; Liu D; Liu Z; Liang Y; Wang Y; Liu Q; Liu Z; Zang Z; Cui Y
J Microbiol Biotechnol; 2020 Jul; 30(7):982-995. PubMed ID: 32347079
[TBL] [Abstract][Full Text] [Related]
12. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.
Blair JM; Bavro VN; Ricci V; Modi N; Cacciotto P; Kleinekathӧfer U; Ruggerone P; Vargiu AV; Baylay AJ; Smith HE; Brandon Y; Galloway D; Piddock LJ
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3511-6. PubMed ID: 25737552
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
[TBL] [Abstract][Full Text] [Related]
14. Binding site feature description of 2-substituted benzothiazoles as potential AcrAB-TolC efflux pump inhibitors in E. coli.
Yilmaz S; Altinkanat-Gelmez G; Bolelli K; Guneser-Merdan D; Ufuk Over-Hasdemir M; Aki-Yalcin E; Yalcin I
SAR QSAR Environ Res; 2015; 26(10):853-71. PubMed ID: 26559566
[TBL] [Abstract][Full Text] [Related]
15. AcrB: a mean, keen, drug efflux machine.
Kobylka J; Kuth MS; Müller RT; Geertsma ER; Pos KM
Ann N Y Acad Sci; 2020 Jan; 1459(1):38-68. PubMed ID: 31588569
[TBL] [Abstract][Full Text] [Related]
16. Perturbed structural dynamics underlie inhibition and altered efflux of the multidrug resistance pump AcrB.
Reading E; Ahdash Z; Fais C; Ricci V; Wang-Kan X; Grimsey E; Stone J; Malloci G; Lau AM; Findlay H; Konijnenberg A; Booth PJ; Ruggerone P; Vargiu AV; Piddock LJV; Politis A
Nat Commun; 2020 Nov; 11(1):5565. PubMed ID: 33149158
[TBL] [Abstract][Full Text] [Related]
17. Design and structural optimization of novel 2H-benzo[h]chromene derivatives that target AcrB and reverse bacterial multidrug resistance.
Wang Y; Alenazy R; Gu X; Polyak SW; Zhang P; Sykes MJ; Zhang N; Venter H; Ma S
Eur J Med Chem; 2021 Mar; 213():113049. PubMed ID: 33279291
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity evaluation of novel 4-subtituted 2-naphthamide derivatives as AcrB inhibitors.
Wang Y; Mowla R; Ji S; Guo L; De Barros Lopes MA; Jin C; Song D; Ma S; Venter H
Eur J Med Chem; 2018 Jan; 143():699-709. PubMed ID: 29220791
[TBL] [Abstract][Full Text] [Related]
19. Efflux-Mediated Resistance to New Oxazolidinones and Pleuromutilin Derivatives in Escherichia coli with Class Specificities in the Resistance-Nodulation-Cell Division-Type Drug Transport Pathways.
Schuster S; Vavra M; Kern WV
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209014
[TBL] [Abstract][Full Text] [Related]
20. A Screening of Antimalarials Extends the Range of Known
Schuster S; Vavra M; Kern WV
Microb Drug Resist; 2022 Dec; 28(12):1065-1070. PubMed ID: 36255442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
